Inflammatory bowel disease

被引:0
|
作者
Herrlinger, K [1 ]
Stange, EF [1 ]
机构
[1] Robert Bosch Krankenhaus, D-70376 Stuttgart, Germany
来源
INTERNIST | 2003年 / 44卷 / 09期
关键词
inflammatory bowel disease; Crohn's disease; ulcerative colitis; immunosuppression; infliximab;
D O I
10.1007/s00108-003-1008-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The etiology of inflammatory bowel diseases is still unknown. However, there seems to be a primary defect in mucosal barrier function resulting in a chronic inflammatory process. Both entities, Crohn's disease and ulcerative colitis show characteristic differences in clinical presentation and laboratory, radiological as well as endoscopical criteria. In some cases of the so called indeterminate colitis a clear distinction may not be possible. Therapy of inflammatory bowel disease aims for a suppression of the mucosal inflammation. Site, extent and especially the course of disease are crucial for the decision when and how to treat the patient. According to the patient's symptoms and disease history topical or systemic application of mesalazine or corticosteroids are used. In case of an intermittent course of disease treatment of the single flare should be started whereas in chronic active disease an immunosuppression with azathioprine, methotrexate or in therapy refractory cases infliximab is warranted.
引用
收藏
页码:1151 / 1171
页数:21
相关论文
共 50 条
  • [31] Better survival of renal cell carcinoma in patients with inflammatory bowel disease
    Derikx, Lauranne A. A. P.
    Nissen, Loes H. C.
    Drenth, Joost P. H.
    van Herpen, Carla M.
    Kievit, Wietske
    Verhoeven, Rob H. A.
    Mulders, Peter F. A.
    Hulsbergen-van de Kaa, Christina A.
    Boers-Sonderen, Marye J.
    van den Heuvel, Tim R. A.
    Pierik, Marieke
    Nagtegaal, Iris D.
    Hoentjen, Frank
    ONCOTARGET, 2015, 6 (35) : 38336 - 38347
  • [32] Clearing of the Clouds in Inflammatory Bowel Disease Management
    Costrini, Nicholas V.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (12) : 3411 - 3417
  • [33] Vaccines and recommendations for their use in inflammatory bowel disease
    Dolores Sanchez-Tembleque, Maria
    Corella, Carmen
    Perez-Calle, Jose L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (09) : 1354 - 1358
  • [34] Biological therapy for chronic inflammatory bowel disease
    Dueker, G.
    Lentze, M. J.
    MONATSSCHRIFT KINDERHEILKUNDE, 2007, 155 (02) : 118 - 126
  • [35] The use of biosimilars in paediatric inflammatory bowel disease
    Jongsma, Maria Myrthe Elisabeth
    Vulto, Arnold
    de Ridder, Lissy
    CURRENT OPINION IN PEDIATRICS, 2017, 29 (05) : 560 - 565
  • [36] What Are the Targets of Inflammatory Bowel Disease Management
    Lega, Sara
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (08) : 1670 - 1675
  • [37] Hepatitis C Virus and Inflammatory Bowel Disease
    Horn, Todd L.
    Reynolds, Joel
    de Villiers, Willem
    Pena, Luis R.
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (06) : 1171 - 1177
  • [38] Precision Medicine in Pediatric Inflammatory Bowel Disease
    Spencer, Elizabeth A.
    Dubinsky, Marla C.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2021, 68 (06) : 1171 - 1190
  • [39] Recent advances in the management of inflammatory bowel disease
    Irving, Peter M.
    CLINICAL MEDICINE, 2009, 9 (06) : 605 - 608
  • [40] The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease
    Avila-Ribeiro, Pedro
    Fiorino, Gionata
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (44) : 6759 - 6769